RT Journal Article
A1 Higashida, Rieko
A1 Imamura, Yutaka
A1 Ishikawa, Atsushi
A1 Tsutsumi, Yorihisa
A1 Ichikawa, Yoshikazu
A1 Wakakuri, Takeshi
A1 Ishida, Masahiro
T1 Intravitreal injection of bevacizumab for diabetic macula edema: morphological and functional outcomes at 1 day after injection.
JF Investigative Ophthalmology & Visual Science
JO Invest. Ophthalmol. Vis. Sci.
YR 2014
VO 55
IS 13
SP 1764
OP 1764
SN 1552-5783
AB  To evaluate and compare the visual and anatomical outcomes in eyes with diabetic macular edema (DME) at 1 day and 1 week after injection of intravitreal bevacizumab. A retrospective, consecutive case series identified 21 consecutive patients with DME undergoing intravitreal injection of bevacizumab. Optical coherence tomography images were taken at the day of injection and 1-day and 1 week after injection. Retinal thickness at fovea and visual acuity were monitored before and after injection. The mean age of patients was 65.1 years old (10 females). Retinal thickness at fovea was 490 ± 169 µm before injection, and was 442 ± 162 µm and 335 ± 148 µm at 1 day and 1 week after injection. (Student t test, P=0.001 and 0.004, respectively) Visual acuity (logMAR) was 0.616±0.344 before injection and 0.682±0.413 and 0.425±0.237 at 1 day and 1 week after injection. (P=0.567 and 0.063, respectively) Resolution of intraretinal fluids was observed at 1 day postoperatively, however at least 1 week is needed so that large amounts of fluids are absorbed in DME. Significant improvement of vision was not observed at 1 day and 1 week after injection. Intraretinal fluids seem to disappear more slowly in DME than those in retinal vein occulusion after intravitreal injection of bevacizumab (Ishikawa A, 2013 ARVO abstract). 
RD 7/25/2021